valu usd unless otherwis note
updat model partnership need
view updat model rais pt
worst appear behind regard cynosur
busi remain show-m stori investor believ
valuat appear reason given compani current growth profil
need addit tuck-in partnership acceler
weight averag market growth rate wamgr estim
wamgr current portfolio asset
md market grow mid-single-digit y/i
done good job reacceler growth breast busi
combin intern develop product brevera
affirm prone intern expansion/distributor acquisit
recent deal faxitron focal slightli
acceler compani wamgr expect execut similar
playbook gyn surgic launch fluid manag
system fda approv new omni hysteroscop
anticip addit expect use partnership
compani like porter instrument delmont imag drive
increment revenu front believ adjac market
like uro pelvic health make sens tuck-in deal gyn
updat estim introduc estim
tweak revenu estim vs
manag guidanc y/i organ
constant currenc basi ep estim move lower
vs manag guidanc y/
separ introduc revenu estim
fce y/i organ constant currenc basi
ep estim fce y/i price target
move impli ebitda ratio vs
large-cap md peer believ discount multipl
rel peer warrant given slower growth profil
worst appear behind valuat appear
reason given compani current growth profil remain
one favor stock large-cap coverag univers
believ worst may behind compani cynosur
previous note bring tempsur vitalia back
market week howev cynosur remain show-m stori
investor believ return market growth cynosur
well tuck-in need near-term drive mid-single-digit y/i
top-line growth multipl re-rat current model
go toward share repurchas leav
remain execut similar
valuat recent faxitron focal deal estim
near-term could acceler top-line growth
dissemin produc price prior trade day market close estimate unless otherwis note
believ share perform line
peer group follow key reason
multipl top-lin growth driver lead us
believ return top-lin growth y/i
medium term
molecular diagnost expect continu
take share hpv expand
trichomona market addit full menu viral
load test doubl holx world-wide molecular market
opportun addit recent brought
panther fusion respiratori assay
regard gyn surgic believ mid-single-digit y/i
growth sustain medium term main
growth driver myosur intern expans
addit believ tuck-in acquisit could expand
two product portfolio segment
intern breast health plenti
opportun convert analog user intern market
system could upgrad separ
intern molecular busi grown y/
recent expect magnitud growth
continu also see opportun increas
current liquid-bas cytolog market share
intern market share
attempt transform sustain growth
compani cynosur growth profil still question
cynosur weak increas novasur competit
continu weigh top-lin growth regard
cynosur sale product ramp quickli
expect recent fda letter led depress
sale sever cynosur product monalisa touch
tempsur vitalia remain sidelin
pend evid reacceler cynosur gyn
risk invest thesi
cynosur growth recov bodi contour
market opportun smaller expect
manag spend drive cynosur
bloomberg capit market estim upside/downside/target
base case price target calcul assign
weight intrins valu calcul
ev/ebitda analysi intrins valu
calcul price-to-earnings analysi
intrins valu calcul dcf
model organ top-lin growth medium
term ep growth y/i assum cynosur
busi return mid-to-high-single-digit y/i revenu
growth also assum molecular diagnost
achiev least high-single-digit y/i growth
upsid scenario valu model organ
top-lin growth next sever year
ep growth in-line peer assum
cynosur busi return high-single-digit y/i revenu
growth period initi sale disrupt
stabil novasur share loss assum
manag drive sustain superior top-lin
growth new contract win product launch
tuck-in
downsid scenario valu model organ top-
line growth low-single-digit rang ep growth
rang assum tomo placement slow
also myosur growth slow competit increases/
near peak sale novasur continu declin due
increas competit endometri ablat market
declin separ assum cynosur sale disrupt
take longer work cynosur revenu growth
continu grow aesthet market growth
medium term final gen-prob revenu growth fall short
expect molecular price pressures/reimburs
pressur increas competitor regain share
deriv price target assign weight intrins
valu calcul ev/ebitda analysi weight intrins
valu calcul price-to-earnings analysi weight intrins valu
calcul dcf analysi point averag forward ev/ebitda
multipl large-cap md compani lifesci tool diagnost averag
ev/ebitda averag forward price-to-earnings multipl large-cap md compani
lifesci tool diagnost averag price-to-earnings assign target non-
gaap ebitda multipl large-cap md peer group
multipl equat intrins valu separ assign target forward
price-to-earnings multipl large-cap md peer group multipl
equat intrins valu believ ev/ebitda price-to-earnings multipl
peer warrant given less visibl abil sustain mid-single-digit y/i top-
line growth rel peer near term final base dcf analysi estim
intrins valu dcf analysi use wacc
termin valu ev/ebitda multipl price target support sector perform
risk rate price target
risk price target rate includ risk meaning delay new product
launch market share loss unforeseen chang regulatori environ
lead develop manufactur supplier diagnost product medic
imag surgic product market corpor headquart locat bedford
skelet health medic aesthet
million except per share data
sell market
gener administr
